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Abstract: 
Dendritic cells (DCs) are responsible for antigen uptake, presentation, and stimulation of 
T cells responsible for recognizing these antigens. During the immature stage DCs endocytose 
fluids and particles from the surrounding interstitial environment, such as the skin, deeper organs, 
and mucous membranes. Maturity is reached after antigen uptake stimulates the loading of 
foreign peptides on their major histocompatibility complex class II (MHC II) molecules, which 
then are expressed on the cell surface. DCs cease antigen uptake and presentation at some point 
after the uptake of a maturation stimulus (antigen); at this point the DC is fully mature. It has 
been estimated that these cells have a 24 hour 
maturation period. However, recent experiments 
suggest that this period is longer than 24 hours. 
Introduction: 
Dendritic cells (also called Langer hans cells) 
are found in the peripheral fluid of organs and 
mucous membranes (Funnel?2002). DCs develop 
from cells known as nonproli:ferating precursors, 
which in turn have evolved from proliferating 
progenitor cells, which are located mainly in the 
bone marrow (Steinman et al. 1999). 
Fig 1 These flourescently-tagged DCs exemplify 
the branching, "dendritic" nature of this type of 
cell (Mellman et al. 1998). 
A DC is characterized by its stellate or dendritic (branching) shape (Fig 1). It has a dark 
nucleus and clear cytoplasm, within which can be found Birbeck granules, whose function are 
currently under study(Funnel?2002). In the immature stage, a DC circulates throughout tissues 
and lymphoid organs, endocytosing material such as self antigens and proteins from its 
surroundings (Steinman and Nuzzen 2001 ). An immature DC is stimulated to begin maturation 
upon endocytosis of a stimulating antigen, (a foreign substance) such as bacterial peptides. 
Stimulated epidermal DCs leave the skin and migrate to draining lymph nodes via lymphatic 
vessels upon bacterial invasion (Shartman 2000) where they initiate an immune response by 
stimulating cytotoxic T lymphocytes (Morrow 2001). Major Histocompatibility Complex (MHC) 
class I and class II molecules are used by DCs to capture and present peptides to T -cells. Class I 
molecules predominantly bind peptides from endogenously synthesized cytosolic proteins and 
class II molecules present peptides derived from internalized degraded material (Nordeng et al. 
1996). During the intermediate stage of maturation, the DC processes and loads the antigen's 
peptides onto its MHC II molecules and transports them to the cell surface (Mellman et al. 1998). 
Once the DC has completed its task of processing and loading large numbers of the antigen 
peptides it is considered a mature cell (Banchereau and Steinman 1998) like the one in Figure 2. 
In this mature state, the peptides presented on its MHC II loaded membrane can be found and 
Fig 2: As dendritic cells mature, antigens are loaded onto MHC II molecules and sent to the surface of the membrane for 
presentation. In these pictures, MHC II molecules are stained green, and can be seen to emerge on the membrane as the cell 
goes from (a) the immature state to (b) the intermediate state, and finally to (c) the mature state (Mellman et al. 200 1 ). 
recognized by lymph node T cells. The branched shape of the DC provides more surface area for 
presentation of peptide toT cells (Mellman and Steinman 2001). 
Each helper T cell (T H) has its own specific T cell receptor designed for a single ligand. 
Helper T cells are attracted by the chemochines released by the DC and are activated when they 
encounter this specific combination ofMHC II and antigen peptide (Cyster et al. 2000). Once 
stimulated, the bound T cell releases interleukin-2 (IL-2) to stimulate other T cells in the vicinity, 
initiating a larger immune system response. 
The time period between initial stimulation and complete maturation has not been 
determined, but has been estimated to be about 24 hours (Inaba et al. 1992). The purpose of this 
study is to determine the maturation time for an antigen stimulated DC. Pigeon cytochrome C 
(PCC) is used as the antigen. The cessation of endocytosis acts is the indicator of maturation 
(Mellman and Steinman 2001 ). 
Dendritic cell study is spread throughout many areas of medical research. Specialized DC 
therapy may play a role in preventing post-donation organ rejection by interacting with donor-
reactive T cells to minimize rejection side effects (Takayama et al. 1999). DCs may play a role in 
vaccines against cancer (Curti et al. 2001). Researchers hope to use DCs to fight tumors by 
isolating patient DCs, culturing/priming them with tumor antigen, and then vaccinating the patient 
with their "educated" DCs (Skin Cancer Foundation 2002). DCs may someday help HIV, AIDS, 
and other patients with immunosuppressive conditions, battle infections against opportunistic 
fungi. Success has already been achieved against the fungus Pneumocystis carinii (Ashkenas 
2001). Research is underway for using DCs to vaccinate against multiple myeloma (Yi et a1. 
2001 ). DCs could someday help prevent or treat diabetes. Specially engineered DCs may be used 
to destroy T-cells which are killing the host's insulin-producing cells (Rossi 2002). However, 
much research remains to be conducted before these procedures can be optimized. This is why 
further research on the details of DC behavior, such as maturation timing, is so badly needed. 
Materials and Methods: 
Cell Line: 
In these experiments AND3 hybridoma T cells were used to recognize I-Ek MHC class II 
molecules expressing PCC 98•104 (the segment of processed PCC peptide containing amino acids 
98 through 104) on the cell membrane. Dendritic cell strain C3D2F1 was used because it could 
present 1-Ek MHC class II molecules. These DCs therefore had the potential ofbeing fed PCC 
and presenting the peptides on I-Ek MHC II molecules in a manner that could stimulate AND3 T 
cells to release IL-2. DCs were isolated in the lab from mouse bone marrow, following lab 
protocol by Inaba et al(1992). T H cells were hybridomas (modified T cells that were fused with 
AND3 lymphoma cells)(Pharmingen) to ensure cell immortality. T cell hybridomas were cultured 
in RPMI (a culture media named after the Roswell Park Memorial Institute) 1640 (Gibco) with 
I 0% heat-inactivated FCS (fetal calf serum), 2mM L-glutamine (Gibco ), 1mM sodium pyruvate 
(Gibco), 1 mM non-essential amino acids (Gibco), 0.75 mM essential amino acids (Gibco), 50 
mM BME (basal medium eagle's) (Sigma), 0.075 glucose (Gibco), and lOmM HEPES (N-2-
Hydroxyethylpiperazine-N' -2-ethanesulfonic acid) (Gibco ). Cells were incubated at 5% COH2, 
37°C. Cells were given fresh media every other day. 
Cell thawing: 
Dendritic cells had been frozen for storage in 1.0 ml vials containing approximately lxl 07 
dendritic cells. Cell vials were removed from liquid nitrogen and placed immediately on ice, to 
prevent shock during their transition from the storage room to the water bath area. Vials were 
shaken in a 37°C water bath until all but a small ice pellet thawed. Cells were then placed in cold 
growth media, allowed to sit on ice for 5 minutes, then centrifuged at 1200 rpm for 5 minutes. 
After aspirating the media, cells were re-suspended at a concentration of 2x1 06 by first tapping in 
residual media and then adding warmed growth media. 
Antigen Presentation: 
Antigen presentation assays were done by exposing post-maturation-stimulated DCs to 
antigen molecules at intervals between 0 and 24+ hours and washing out antigen three hours later 
following preparation, buffering, and concentrations as described in the antigen presentation 
laboratory protocol by Buus et al(1986). Intervals varied for each assay; the first covered from 2 
to 10 hours after exposure, the second from 14 to 28 hours, the third from 24 to 3 6 hours, and 
the fourth from 6 to 20 hours. DCs were first given LPS (lipopolysaccharide: a bacterial 
membrane component extracted from L. monocytogenes), or ovalbumin as their maturation 
stimulus. These samples were then each pulsed with PCC, (which also contains LPS) at intervals 
between 0 and 36 hours. T cells responsible for recognizing antigen-loaded MHC lis were 
immediately added to DCs at a 1:1 ratio and incubated at 37°C, 5% C02 for 24 hours. In this 
experiment, presentation of?PCC was tested by antigen presentation assays using the AND3 
hybridoma T cells, which released IL-2 when stimulated by contact with presented PCC peptides. 
Levels ofhybridoma activation were measured by averaging anti-IL2 ELISA concentrations from 
all the wells of each time period or standard, a total which represented the antigen presentation of 
approximately 90 DCs per group. 
Cluster disruption technique: 
In later experiments it became necessary to ensure that all DCs had truly received a 
maturation stimulus at the same time. As an additional maturations stimulus, a P1000 pipet was 
used to triturate DC samples ten times three hours after the addition of antigen. This disturbance 
stimulated the cells to enter the intermediate phase without antigen uptake. 
ELISA: 
Twenty-four-hour supernatants from antigen presentation (AP) assays were collected by 
micropipet and transferred to fresh plates after centrifugation of the original plates at 1500 RPM 
for 5 minutes. Supernatants were frozen at -80°C overnight before use. Anti-IL-2 ELISA protocol 
was followed according to manufacturer instructions (Pharmingen) to measure T cell stimulation. 
Plates were read with an optical density of 450 nm. 
Antigens/reagents: 
Anti-CD3, anti-CD28, anti-IL-2 (biotinylated and unconjugated) were obtained from 
Pharmingen; PMA (phorbol-myristate-acetate), calcium ionophore, ovalbumin, PCC, and LPS 
were purchased from Sigma. Streptavidin-horseradish peroxidase was from Zymed. 
Controls: 
Each experiment's plate contained wells with several positive and negative controls for 
both dendritic cells and T cells. Positive DC controls included maturation only by PCC to ensure 
that these DCs were indeed capable of processing entire PCC molecules, presenting the processed 
peptides, and stimulating the proper T cells. Mature DC surface MHC II molecules were loaded 
with MCC-peptide (moth cytochrome c-peptide: differing from PCC-peptide in only one amino 
acid) to ensure that pre-processed peptides had no trouble being loaded and presented on MHC II 
molecules. Positive T cell controls included exposing T cell wells to PMA + calcium ionophore 
(P/?) and stimulating other wells with antibodies recognizing the T cell receptors CD3 and CD28 
(co stimulatory molecules also necessary for successful T cell activation). Negative controls 
included samples ofDCs + LPS (without PCC), T cells only, and DCs only. 
Results: 
Because the supernatants of the assays were diluted at various ratios, each was judged by 
its own respective scale (set by the standards and controls used on each plate) to measure IL-2 
levels, and was not compared with the scales of the other graphs. Ratios varied due to the 
number ofDCs used in each assay, each chosen to best fit the respective amount of??L-2 that was 
going to be measured. The more cells that were available for the assay, the higher the dilution of 
the supernatants to avoid oversaturation. The ratios were not always a perfect match, however, 
resulting in some variance in scales between the graphs. Assays two and four had a dilution of 1 : 1, 
so their IL-2 values fell between 1 and 2 ng/m. Assay three had a dilution of 1:5, and had a range 
of??L-2 values between 1.5 and 3 ng/ml. Assay one had a dilution of 1 :2, and had a range of??L-2 
levels between 1.5 and 4.5 ng/ml. 
AP assay 1 involved pulsing dendritic cells at time points between 2 and 10 hours after the 
maturation stimulus (LPS) was given. In the samples of?PCC-pulsed DCs + AND3 T cells, a 
rising titer was observed between these time points (Figure 3). As the time between stimulation 
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Figure 3: T cells reacting with DCs that were pulsed with PCC up to ten hours after receiving a maturation 
stimulus show a rising titer of??L-2. 
1.8 
??
1.6 
1.4 
~ 
E 1.2 -OJ 
..s 
I i 
I I 
I 
N 1.0 
'= 32 
::I 0.8 ~ 
CD 
"E 0.6 
0.4 
l! I 
I I I II ~ I '1 1 i I 
I 
0.2 
0.0 "' 14 18 28 
Hours After Maturation Stimulus 
Fig 4: T cells reacting with DCs that were pulsed with PCC up to 28 hours after receiving maturation stimulus 
still show high levels ofll..-2. 
and antigen introduction increased, so did the amount of interleu.kin-2 released by the T cells in 
response to increased antigen presentation on the dendritic cells' surfaces. IL-2levels increased 
approximately 2.5 times between the first and final readings. 
AP assay 2 dealt with time points after 1 0 hours, measuring antigen presentation up to 28 
hours after the introduction of the maturation stimulus (Figure 4). AND3 T cells continued to 
show significant levels of activation up to the 28 hour time point. There was a small drop in IL-2 
levels between the 18 and 28 hour time periods. However, because this drop was small and 
because this 18 hour level of??L-2 still fell within acceptable IL-2 levels set by the positive 
controls on that plate, the IL-2 levels at 28 hours still indicated actively endocytosing and antigen-
presenting dendritic cells. 
At this point in the experiment, it became necessary to examine the possibility that our 
previous results were misleading. Because DCs tend to form clusters along the sides and bottom 
of the wells as they multiply, it could have been possible that the cells inside the clusters were 
receiving the maturation stimulus later than those outside or were hiding DC precursors, making it 
appear that maturation took longer than it really did. Since these inner cells would take longer to 
mature than those outside the cluster, they could have given the illusion that DC uptake continued 
past 24 hours. To test the reliability of our previous results, the cluster disruption technique (see 
materials and methods) was employed on AP assay 3. An ELISA of this assay indicated antigen 
presentation up to 36 hours after the initial PCC stimulation (Figure 5). There was a slight drop 
in IL-2 at the 29 hour period, but it still fell within acceptable IL-2levels set by the positive 
controls on that plate. 
Because the maturation period still appeared to be extending much father than the 
estimated 24 hour period, further measures were taken to ensure that all the dendritic cells 
received the maturation stimulus at the same time, since it was believed that clusters of cells could 
reform following disruption. Since dendritic cells break away from their clusters when they 
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Figure 5: T cells reacting with DCS that were pulsed with PCC up to 36 hours after receiving maturation stimulus 
still show high levels of??L-2. 
receive a stimulus, AP assay 4 was conducted using only free floating dendritic cells; those 
clustering around the walls of the wells were discarded since it was not certain if all of them 
received the maturation stimulus (LPS) at the same time. Up to 20 hours after stimulation the 
DCs were still presenting antigen and showed no decline of??L-2 levels (Figure 6). However, the 
drop in the 10 hour period is a significant drop, but why it happened could not be determined. It 
is probably due to some unknown experimental error stemming from the care or handling of this 
sample of cells. 
Due to time restraints, post-20 hour experimentation with free floating cells was not able 
to be explored. 
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Figure 6: IL-2 levels show no overall decline from T cells reacted with free floating DCs. 
Discussion: 
The overall resuhs from the antigen presentation assays indicate that dendritic cell 
maturation may take longer than the estimated 24 hour period. The first three experiments 
showed high levels ofinterleukin-2 past 24 hours, even up to 36 hours in AP assay 3, with no sign 
of decline. Except for slight IL-2 variations still within levels set by positive controls in AP assays 
2 and 3, or the one large drop in IL-2 in AP assay 4 due to experimental error, there was no 
telltale drop in IL-2 levels that would indicate that dendritic cell endocytosis had ceased. 
However, because of time constraints and many other AP assays that were lost due to 
various experimental errors or faulty materials, research concerning the clustering effect ofDCs 
on these experiments was not completed. Because there was only time to test maturation with 
free floating cells up through 10 hours, it cannot be said with certainty that DCs take longer than 
) 24 hours to mature. 
Future research should focus on repeating these experiments to verify their results, testing 
this hypothesis that the maturation ofDCs requires longer than 24 hours. Future research should 
explore the possibility that DC precursors were present throughout the experiments and 
influencing the IL-2 resuhs. To do this researchers would need to separate precursors from DC 
samples. This can be done by coating metallic beads with antibodies to CD 11 c (a ''marker 
molecule" only present on DCs), exposing DC solutions to these beads, and placing the cells over 
a magnetic column to extract only DCs and yield a pure population. 
The effect of antigen concentration in maturing DCs also needs to be further studied. It 
may be that the concentrations used in these experiments were too high, saturating the DCs with 
antigen, which may have led to the appearance of antigen uptake and presentation past the true 
) point of maturation 
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DC Proposal 
Introduction/Background: 
Dendritic cells (DCs) are a crucial participant in the humoral immune system_ Their 
primary function is screening body tissue/fluids for foreign antigens, and, if an antigen is found, 
activating the proper T cells programmed to respond to that specific antigen_ 
Early, or immature DCs are found throughout the periphery of the body, such as the skin, 
where "enemy'' organisms can easily enter and infect the body. It is in this stage that a DC is 
most active in endocytosing particles in its surrounding environment_ These particles are 
transported to lysosomes within the DC Here, the particles are degraded to simpler peptide 
molecules_ These peptides (or antigens), if of foreign origin (such as a virus, bacteria, etc), will 
alert the DC to begin maturation_ 
The DC now leaves the periphery of the body (skin) and enters the lymphatic system, 
• 
making its way toward the lymph nodes_ At this intermediate stage, the cell begins to load the 
"enemy" peptides onto its MHC (major histocompatability) IT molecules and to transport them to 
??
the surface of the cell, the plasma membrane. The point in the intermediate phase where the DC 
stops endocytosis and begins costimulatory action has not yet been determined. 
Once within the lymph nodes, the DC has now entered the late or mature phase. 
Endocytosis has dramatically decreased at this point. Displaying the peptides on its membrane 
surface, the mature DC is able to activate the peptide-specific T cells upon contact. An early 
indication ofT cell activation is its product ion ofinterleukin-2 (IL-2). 
Proposal: 
In studying these processes, I seek to answer two questions. First, how many hours after 
} 
the initiation of maturation will a DC continue to actively endocytose and present foreign 
antigens? Second, is it possible for a DC to successfully uptake and display two different antigens 
such that it will then successfully stimulate both respective T cells? 
Procedures: 
The DC cells under study are from strain, C3D2Fl, selected specifically because they 
present both 1-Ek and l-Ad classes ofMHC II molecules. Ovalbumin and PCC act as the two 
antigens in this experiment. NF AT and AND3 act as their respective T cells, AND3 recognizing 
1-Ek + PCC 89-104, and NFAT recognizing I-A11 +Ova 323-339 (where the superscripts 89 - 104 and 
323- 339 refer to the specific amino acid sequences taken from the antigen and loaded unto the 
MHC II molecules). 
In a series of antigen presentation assays, DCs will be initially stimulated by LPS (for 
single antigen uptake study), or ovalbumin or PCC (for double antigen uptake study). These 
samples will be individually pulsed with the second antigen after 2 hrs, 4 hrs, 6 hrs, 8 hrs, etc. up 
to at least 24 hrs. To distinguish between AND3 and NFAT stimulation, each will be added to 
separate wells for each time point. Anti-IL-2 ELISA tests will measure the amount of IL-2 
production, a measure ofT cell stimulation (and thus, antigen presentation) after the set time 
point of antigen uptake. By studying IL-2 levels from each T -cell strain at each time point, I hope 
to find when antigen uptake ceases, as indicated by a drop in IL-2levels. By studying IL-2 levels 
for each T -cell strain in samples where both antigens were given, I hope to determine whether the 
DCs are capable of presenting both antigens. 
